Skip to main content

Table 1 Drug use evaluation of cefepime in 96 and 111 patients during cycle A and cycle B, respectively

From: Drug use evaluation of cefepime in the first affiliated hospital of Bengbu medical college: a retrospective and prospective analysis

Items

Number of patients (of 96) consistent with the standards in cycle A

Number of patients (of 111) consistent with the standards in cycle B

Indication

81 (84.38%)

105 (94.59%)

Drug monitoring

Ā Ā 

ā€ƒLife index record

96 (100%)

111 (100%)

ā€ƒBlood examination

85 (88.54%)

108 (97.30%)

ā€ƒLiver function monitoring

75 (78.12%)

101 (90.99%)

ā€ƒRenal function monitoring

72 (75.00%)

107 (96.40%)

ā€ƒBacterial culture and sensitivity test

60 (65.22%)*

98 (88.29%)

ā€ƒDrug skin test

96 (100%)

111 (100%)

Dosage

Ā Ā 

ā€ƒDose and duration

70 (72.92%)

100 (90.09%)

ā€ƒDosing frequency

70 (72.92%)

100 (90.09%)

ā€ƒSolvent selection

96 (100.00%)

110 (99.10%)

ā€ƒRoute of administration

96(100.00%)

111 (100.00%)

ā€ƒCompatibility

95 (98.96%)

111 (100.00%)

Replacement drugs

84 (87.50%)

104 (93.69%)

Combined medication (drug-drug interaction)

58 (62.37%)*

89 (80.18%)

Adverse drug reactions

8 (8.33%)

7 (6.31%)

Outcome

83 (91.21%)

102 (95.33%)

  1. *Some cases could not be evaluated, and the percentage was calculated from the cases that could be evaluated.